Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C

IMPORTANCE: Recent reports based on the US Food and Drug Administration’s voluntary Adverse Events Reporting System raised questions about the safety of direct-acting antivirals (DAAs) for treatment of the hepatitis C virus (HCV). OBJECTIVE: To assess the rates of adverse events in patients with HCV...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Netw Open
Autori principali: McGlynn, Elizabeth A., Adams, John L., Kramer, Jason, Sahota, Amandeep K., Silverberg, Michael J., Shenkman, Elizabeth, Nelson, David R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2019
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563580/
https://ncbi.nlm.nih.gov/pubmed/31173117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.4765
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi